Lyra Therapeutics inks $29.5 mln Series B
Boston-based Lyra Therapeutics Inc, a developer of medicines to treat ear, nose and throat diseases, has secured $29.5 million in Series B financing. Perceptive Advisors led the round with participation from other investors that included RA Capital Management, ArrowMark Partners, Soleus Capital, Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners.
26 September 2018•1 min read
